![\"\"](\"https:\/\/www.merckconnect.com\/idvynso\/wp-content\/uploads\/sites\/338\/2026\/08\/Full-Overlay-desk_d25180.png?w=1232\")
<\/picture>Trial 051: LDL-C and non-HDL-C data for IDVYNSOTM<\/sup> \u2028(doravirine\/islatravir) and oral baseline ART through week 48<\/h1><\/p>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n\n\n\n<\/div>\n\n\n\n\nLimitations1,2<\/sup>:<\/strong><\/h3><\/div>\n\n\n\n<\/div>\n\n\n\n\n- Participants on lipid-lowering therapy were excluded.<\/li>
- For those who initiated lipid-lowering therapy during the study, only measurements collected before the initiation of lipid-lowering therapy were included in the analysis.<\/li><\/ul><\/div>\n\n\n\n<\/div>\n\n\n\n
The clinical benefits of these findings have not been demonstrated.<\/strong><\/p>\n\n\n\n<\/div>\n\n\n\n\n<\/div>\n\n\n\n\nMean Change in Fasting LDL-C and Non-HDL-C From Baseline to Week 48 in Trial 051 \u2028in Participants Who Were Not on Lipid-Lowering Agents2<\/sup><\/strong><\/h3><\/div>\n<\/div>\n\n\n\n<\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n\n<\/th> IDVYNSO<\/th> Oral Baseline ART<\/th> Difference (95% CI)a<\/sup><\/th>p<\/em> valueb<\/sup><\/strong><\/th><\/tr><\/thead>Protease-inhibitor-based regimens<\/td> (n=10)<\/strong><\/td>(n=4)<\/strong><\/td><\/td> <\/td><\/tr> LDL cholesterol<\/td> -7.1 (-27.1 to 12.9)<\/td> -2.8 (-9.9 to 4.4)<\/td> -2.2 (-24.9 to 20.5)<\/td> 0.83<\/td><\/tr> Non-HDL cholesterol<\/td> -11.8 (-32.0 to 8.4)<\/td> -2.8 (-10.9 to 5.4)<\/td> -7.0 (-29.8 to 15.8)<\/td> –<\/td><\/tr> NNRTI-based regimens<\/td> (n=69)<\/strong><\/td>(n=41)<\/strong><\/td><\/td> <\/td><\/tr> LDL cholesterol<\/td> 5.1 (-0.8 to 10.9)<\/td> 0.3 (-5.9 to 6.5)<\/td> 3.4 (-5.1 to 12.0)<\/td> 0.43<\/td><\/tr> Non-HDL cholesterol<\/td> 5.8 (-0.4 to 12.0)<\/td> 0.4 (-6.5 to 7.4)<\/td> 4.0 (-5.2 to 13.2)<\/td> –<\/td><\/tr> INSTI-based regimens<\/td> (n=156)<\/strong><\/td>(n=84)<\/strong><\/td><\/td> <\/td><\/tr> LDL cholesterol<\/td> 2.5 (-0.7 to 5.6)<\/td> -0.4 (-5.0 to 4.3)<\/td> 3.7 (-1.5 to 9.0)<\/td> 0.16<\/td><\/tr> Non-HDL cholesterol<\/td> 3.6 (0.1 to 7.1)<\/td> 3.3 (-5.9 to 12.4)<\/td> 1.0 (-6.8 to 8.9)<\/td> –<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\nData are mean mg\/dL (95% CI) unless otherwise indicated.<\/p><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\na<\/sup>The 95% confidence intervals for the treatment difference were calculated from ANCOVA models with terms for baseline measurement and treatment.<\/p><\/div><\/div>\n\n\n\n\u2028b<\/sup>Mean changes in non-HDL cholesterol concentrations from baseline to Week 48 were not formally stastically tested. The LDL cholesterol analysis was prespecified with multiplicity control.<\/p><\/div><\/div>\n\n\n\n<\/div>\n\n\n\n\n
\n\n\n\n<\/div>\n\n\n\nContinue exploring Trial 051<\/h2><\/div>\n\n\n\n
Limitations1,2<\/sup>:<\/strong><\/h3><\/div>\n\n\n\n<\/div>\n\n\n\n\n- Participants on lipid-lowering therapy were excluded.<\/li>
- For those who initiated lipid-lowering therapy during the study, only measurements collected before the initiation of lipid-lowering therapy were included in the analysis.<\/li><\/ul><\/div>\n\n\n\n<\/div>\n\n\n\n
The clinical benefits of these findings have not been demonstrated.<\/strong><\/p>\n\n\n\n<\/div>\n\n\n\n\n<\/div>\n\n\n\n\nMean Change in Fasting LDL-C and Non-HDL-C From Baseline to Week 48 in Trial 051 \u2028in Participants Who Were Not on Lipid-Lowering Agents2<\/sup><\/strong><\/h3><\/div>\n<\/div>\n\n\n\n<\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n\n<\/th> IDVYNSO<\/th> Oral Baseline ART<\/th> Difference (95% CI)a<\/sup><\/th>p<\/em> valueb<\/sup><\/strong><\/th><\/tr><\/thead>Protease-inhibitor-based regimens<\/td> (n=10)<\/strong><\/td>(n=4)<\/strong><\/td><\/td> <\/td><\/tr> LDL cholesterol<\/td> -7.1 (-27.1 to 12.9)<\/td> -2.8 (-9.9 to 4.4)<\/td> -2.2 (-24.9 to 20.5)<\/td> 0.83<\/td><\/tr> Non-HDL cholesterol<\/td> -11.8 (-32.0 to 8.4)<\/td> -2.8 (-10.9 to 5.4)<\/td> -7.0 (-29.8 to 15.8)<\/td> –<\/td><\/tr> NNRTI-based regimens<\/td> (n=69)<\/strong><\/td>(n=41)<\/strong><\/td><\/td> <\/td><\/tr> LDL cholesterol<\/td> 5.1 (-0.8 to 10.9)<\/td> 0.3 (-5.9 to 6.5)<\/td> 3.4 (-5.1 to 12.0)<\/td> 0.43<\/td><\/tr> Non-HDL cholesterol<\/td> 5.8 (-0.4 to 12.0)<\/td> 0.4 (-6.5 to 7.4)<\/td> 4.0 (-5.2 to 13.2)<\/td> –<\/td><\/tr> INSTI-based regimens<\/td> (n=156)<\/strong><\/td>(n=84)<\/strong><\/td><\/td> <\/td><\/tr> LDL cholesterol<\/td> 2.5 (-0.7 to 5.6)<\/td> -0.4 (-5.0 to 4.3)<\/td> 3.7 (-1.5 to 9.0)<\/td> 0.16<\/td><\/tr> Non-HDL cholesterol<\/td> 3.6 (0.1 to 7.1)<\/td> 3.3 (-5.9 to 12.4)<\/td> 1.0 (-6.8 to 8.9)<\/td> –<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\nData are mean mg\/dL (95% CI) unless otherwise indicated.<\/p><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\na<\/sup>The 95% confidence intervals for the treatment difference were calculated from ANCOVA models with terms for baseline measurement and treatment.<\/p><\/div><\/div>\n\n\n\n\u2028b<\/sup>Mean changes in non-HDL cholesterol concentrations from baseline to Week 48 were not formally stastically tested. The LDL cholesterol analysis was prespecified with multiplicity control.<\/p><\/div><\/div>\n\n\n\n<\/div>\n\n\n\n\n
\n\n\n\n<\/div>\n\n\n\nContinue exploring Trial 051<\/h2><\/div>\n\n\n\n
- Participants on lipid-lowering therapy were excluded.<\/li>
- For those who initiated lipid-lowering therapy during the study, only measurements collected before the initiation of lipid-lowering therapy were included in the analysis.<\/li><\/ul><\/div>\n\n\n\n<\/div>\n\n\n\n
The clinical benefits of these findings have not been demonstrated.<\/strong><\/p>\n\n\n\n
<\/div>\n\n\n\n\n<\/div>\n\n\n\n\nMean Change in Fasting LDL-C and Non-HDL-C From Baseline to Week 48 in Trial 051 \u2028in Participants Who Were Not on Lipid-Lowering Agents2<\/sup><\/strong><\/h3><\/div>\n<\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n\n<\/th> IDVYNSO<\/th> Oral Baseline ART<\/th> Difference (95% CI)a<\/sup><\/th> p<\/em> valueb<\/sup><\/strong><\/th><\/tr><\/thead> Protease-inhibitor-based regimens<\/td> (n=10)<\/strong><\/td> (n=4)<\/strong><\/td> <\/td> <\/td><\/tr> LDL cholesterol<\/td> -7.1 (-27.1 to 12.9)<\/td> -2.8 (-9.9 to 4.4)<\/td> -2.2 (-24.9 to 20.5)<\/td> 0.83<\/td><\/tr> Non-HDL cholesterol<\/td> -11.8 (-32.0 to 8.4)<\/td> -2.8 (-10.9 to 5.4)<\/td> -7.0 (-29.8 to 15.8)<\/td> –<\/td><\/tr> NNRTI-based regimens<\/td> (n=69)<\/strong><\/td> (n=41)<\/strong><\/td> <\/td> <\/td><\/tr> LDL cholesterol<\/td> 5.1 (-0.8 to 10.9)<\/td> 0.3 (-5.9 to 6.5)<\/td> 3.4 (-5.1 to 12.0)<\/td> 0.43<\/td><\/tr> Non-HDL cholesterol<\/td> 5.8 (-0.4 to 12.0)<\/td> 0.4 (-6.5 to 7.4)<\/td> 4.0 (-5.2 to 13.2)<\/td> –<\/td><\/tr> INSTI-based regimens<\/td> (n=156)<\/strong><\/td> (n=84)<\/strong><\/td> <\/td> <\/td><\/tr> LDL cholesterol<\/td> 2.5 (-0.7 to 5.6)<\/td> -0.4 (-5.0 to 4.3)<\/td> 3.7 (-1.5 to 9.0)<\/td> 0.16<\/td><\/tr> Non-HDL cholesterol<\/td> 3.6 (0.1 to 7.1)<\/td> 3.3 (-5.9 to 12.4)<\/td> 1.0 (-6.8 to 8.9)<\/td> –<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n Data are mean mg\/dL (95% CI) unless otherwise indicated.<\/p><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\na<\/sup>The 95% confidence intervals for the treatment difference were calculated from ANCOVA models with terms for baseline measurement and treatment.<\/p><\/div><\/div>\n\n\n\n
\u2028b<\/sup>Mean changes in non-HDL cholesterol concentrations from baseline to Week 48 were not formally stastically tested. The LDL cholesterol analysis was prespecified with multiplicity control.<\/p><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n\n
\n\n\n\n<\/div>\n\n\n\nContinue exploring Trial 051<\/h2><\/div>\n\n\n\n